Objective: To test whether glucocorticoids inhibit sympathetic nerve activity or norepinephrine release in humans, as has been suggested by results in laboratory animals. Methods: This was a double-blind, placebo-controlled, randomized crossover study performed at the Clinical Center o f the National Institutes o f Health, Thirteen normal volunteers received 20 mg pred nisone or placebo orally each morning for 1 week, followed by a washout period o f 1 week and then by treatment with the other drug for 1 week. On the last day o f cach treatment week, blood samples were drawn for measurements o f plasma levels o f catecholamines and their metabolites, o f cortisol, and o f corticotropin at baseline and during reflexive sympathetic stimulation elicited by lower body negative pressure ( -15 mm H g). A 24-hour urine collection was obtained at the end o f each week o f treatment for measurement o f urinary excretion o f catechols. In eight subjects, directly recorded peroneal skeletal muscle sympathetic nerve activity was also measured after both treatments. Remits: Prednisone significantly decreased sympathetic nerve activity by 23% ± 6%, plasma norepineph* tine levels by 27% ± 6%, and plasma corticotropin levels by 77%. Blood pressure, heart rate, body weight, and urinary excretion of catechols and electrolytes were unaffected. Prednisone did not alter pro portionate increments in sympathetic nerve activity or plasma norepinephrine levels during lower body negative pressure. Relationships between sympathetic nerve activity and plasma norepinephrine levels were unchanged. The hypothalarno-pituitary-adrenocortical (HPA), sympathoneural, and adrenomedullary systems inter act complexly to maintain homeostasis. Exogenously administered glucocorticoids are well known to inhibit HPA activity. This study focused on effects of exoge nously administered glucocorticoids on sympathoneu ral function.
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adrenergic responses to immobilization.1,2 fects are associated with decreased catecholamine syn thesis and decreased norepinephrine release in brain. 3 In humans, Stene et al. 4 found that oral methasone decreased plasma norepinephrine levels at baseline and during orthostasis, whereas Rupprecht et al,s and Scherrer et al.6 did not. Scherrer et al. 6 reported that dexamethasone did not affect directly re corded skeletal muscle sympathetic nerve activity at baseline or during the cold pressor test. Sudhir et a l. 7 reported that oral hydrocortisone treatment for 1 at a dose of 200 mg/day increased systolic blood pres sure and enhanced forearm vascular responses to in» traarterial norepinephrine but did not significantly alter estimated rates of norepinephrine spillover into arterial or forearm venous plasma.
We examined the effects of 1 week of oral treat ment with prednisone on plasma levels of and on sympathetic nerve activity, during resting con ditions and in response to lower body negative pres sure, in a double-blind, placebo-controlled, random ized crossover study of healthy adult volunteers. The study was designed to determine whether 1 week of glucocorticoid administration to humans would affect sympathetic nerve activity, plasma norepinephrine levels, or urinary norepinephrine excretion and whether the extents of these effects would be propor tionately similar. The study also addressed whether prednisone treatment alters sympathetic nerve activity or norepinephrine responses to lower body negative pressure, a laboratory model of orthostasis that de creases cardiac filling and reflexively increases sympa thoneural outflow. 8 
METHODS

Subjects.
Thirteen healthy volunteers (10 men and three women; mean age, 33 years; age range, 21 to 54 years) participated in the study after each gave written informed consent. Each subject had a normal medical history, physical examination, screening laboratory tests of blood and urine, and electrocardiogram (ECG). The participants refrained from smoking and from drinking alcohol or caffeinated beverages for 24 hours before each testing session. The study protocol was approved by the Intramural Research Board of the National Institute of Neurological Disorders and Stroke.
Study design. All subjects were studied twice: after 20 mg prednisone each morning for 7 days and after placebo for 7 days. The sequence of the double-blind treatments was randomized. Between the treatments there was a washout period of 7 days. A testing ses sion occurred on the last day of each treatment. The subjects were advised to take the last dose 1 to 2 hours before the testing session. The chosen dose of pred nisone is known to suppress HPA activity. 9 On the morning of each testing session, each sub ject delivered a 24-hour collection of spontaneously voided urine in a container to which 30 ml of 6 mol/L hydrochloric acid had been added. The urine volume was recorded and an aliquot frozen for assays of levels of catechols, creatinine, sodium, and potassium.
Setup. The experiments were conducted in a quiet room with constant temperature (about 24° C) and with the subjects in the supine position. Blood pres sure was measured with an automated cuff device (Critikon, Inc., Tampa, Fla.). Heart rate was recorded continuously by ECG. An intravenous catheter was in serted for sampling blood.
Microneurography. In eight subjects, multifiber re cordings of sympathetic nerve activity were obtained successfully after both drug treatments from a muscle CLINICAL PHARMACOLOGY & THERAPEUTICS VOLUME 58, NUMBER 1 fascicle of the peroneal nerve at the head of the fibula. The right and left peroneal nerves were used alterna tively for the two study sessions. The course of the nerve was mapped with transcutaneous electrical stimulation (40 to 60 V, 0.2 msec, 1 Hz) with use of a pencil-shaped electrode. A sterile tungsten-wire microelectrode was inserted in the region of the nerve. A similar reference electrode was inserted subcutaneously 1 to 3 cm from the recording electrode. Weak electrical stimuli (2 to 4 V, 0.2 msec, 1 Hz) were de livered to the recording electrode with a stimulator connected to an isolation unit. The elicitation of invol untary twitches in the lower leg indicated that the electrode tip was located within or close to the muscle nerve fascicle. The electrode was then moved until there was acceptable recording from sympathetic nerve fibers. Recording of sympathetic nerve activity was accepted if (1) tapping or stretching the muscles or tendons supplied by the impaled nerve produced af ferent mechanoreceptor discharges, while rubbing the skin in the sensory field of the nerve evoked no affer ent response, and (2) spontaneous, pulse-synchronous bursts of muscle sympathetic nerve activity were ob served, with the frequency and amplitude of the bursts increasing during held expiration but not during arousal stimuli. Electrodes remained in place through out the study. The electrodes were connected to a preamplifier (gain, 1000) and an amplifier (gain, 70). The nerve signals were played through a loudspeaker, displayed on a monitor, and recorded with the MacLab/8 data recording system (ADInstruments, Castle Hill, Australia) and a Macintosh computer. The number and the amplitude of sympathetic bursts were measured during 5-minute periods and expressed in bursts per minute and microvolts per minute. The measurements were performed with use of Chart and Peaks software from ADInstruments.
Lower body negative pressure. The legs and lower abdomen of the subject were enclosed in a specially designed lower body negative pressure chamber, with a hinged door permitting access to the leg for nerve recordings (Medical Instruments, University of Iowa, Iowa City, Iowa). The chamber was sealed around the upper abdomen of the subject with plastic sheeting and was attached to a vacuum motor.
JExperimental protocol. After the subject had been at supine rest for at least 15 minutes, blood pressure was recorded each minute and heart rate and sympa thetic nerve activity were recorded continuously for 5 minutes. Baseline blood samples (about 10 ml) were drawn. Lower body negative pressure was then ap plied at -15 mm Hg for 15 minutes. Blood pressure was recorded each minute, and heart rate and sympa thetic nerve activity were recorded continuously for the last 5 minutes of lower body negative pressure. In the last minute of lower body negative pressure, an other blood sample was drawn.
Assays. Blood samples were collected into chilled heparinized glass tubes and centrifuged at 4° C and 3500# for 15 minutes before storage of the plasma at -7 5° C until assayed. Plasma and urine levels of cat echols were assayed by liquid chromatography with electrochemical detection after adsorption on alumi num oxide.10,11 The limits of detection were about 0.04 nmol/L for norepinephrine and about 0.06 nmol/L for epinephrine. Intraassay and interassay co efficients of variation for catechol assays in this labo ratory have been published previously.10 Urine con centrations of creatinine, sodium, and potassium were assayed according to standard clinical laboratory methods. Serum cortisol levels were measured by ra dioimmunoassay (Quanticoat, Kallestad Diagnostics, Chaska, Minn.). The antibody crossreacts minimally with prednisone at 0.39% and has a sensitivity of 0.5 |xg/dl. The intraassay coefficient of variation (CV) was less than 10%. Plasma corticotropin levels were measured by a highly specific two-site radioimmuno assay (Nichols Institute Diagnostics, San Juan Capis trano, Calif.) with a sensitivity of 1 pg/ml and intra assay coefficient of variation of less than 5%.
Data analysis. Results are presented as mean values ±SE. Responses were expressed both as absolute and \ as percentage changes from the resting values. Paired t tests were used to compare the effects of prednisone on basal values and to assess the effects of lower body negative pressure during each treatment. Two-way ANOVA was used to test for interactions between prednisone treatment and responses to lower body negative pressure. The average coefficient of correla tion between sympathetic nerve activity and plasma norepinephrine levels was calculated using the Fisher z transformation. A p value less than 0.05 defined sta tistical significance.
RESULTS
Effects o f prednisone. Predr a dose of 20 mg each morning feet systolic, diastolic, or mean blood pressures, heart rate, or body weight (Table I) . Plasma cortisol levels averaged 9.9 ± 1.3 |xg/dl during placebo and 8.6 ± 1.4 |ig/dl during prednisone (difference not signifi cant). Plasma corticotropin levels decreased by a mean of 77%, from 25.2 ± 5.6 to 5.1 ± 1.3 pg/ml (p < 0.01).
For all eight subjects in whom microneurographic recordings were obtained successfully after both treat ments, prednisone suppressed sympathetic nerve ac tivity (Table I) There were no statistically significant differences in values for the above indexes between the placebo and prednisone treatments. nerve activity in the two study sessions were closely related, and the slopes of the regression lines were close to 1 (Fig. 1, A) .
Plasma norepinephrine levels decreased signifi cantly by 27% ± 6% during prednisone treatment. Plasma norepinephrine levels were positively corre lated between the two treatments (Fig. 1, B) \ the slopes of the regression lines for plasma norepineph rine levels were significantly smaller than 1. Pred nisone also significantly decreased plasma levels of di hydroxy phenylgly col (DHPG) by 18% ± 5% and dihydroxyphenylalanine (DOPA) by 15% ± 4%. Prednisone did not significantly alter plasma levels of epinephrine or dihydroxyphenylacetic acid (DOPAC, Table I ).
Prednisone treatment did not affect 24-hour urinary excretion rates of norepinephrine or of other catechols (Table II) . The 24-hour urinary excretion rates of so dium, potassium, and creatinine did not differ be tween the two treatment phases.
Effects o f lower body negative pressure. After pla cebo treatment, lower body negative pressure pro duced slight but consistent decreases (p < 0.01) in systolic blood pressure, without affecting diastolic or mean blood pressure or heart rate ( Table I) .
Lower body negative pressure increased sympa thetic nerve activity and plasma norepinephrine levels in all subjects. Sympathetic nerve activity increased by 20% ± 6% when expressed as bursts per minute and by 58% ± 19% when expressed as microvolts per minute (Fig. 2) . Plasma norepinephrine levels increased by 27% dihydroxyphenylgly col levels increased slightly and nonsignificantly by i K
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Effects o f prednisone on responses to lower body negative pressure. After prednisone treatment, lower body negative pressure did not affect systolic, dia stolic or mean blood pressures and slightly but consis tently increased heart rate ip < 0.01; Table I ). ANOVA indicated a significant effect of prednisone treatment on responses of systolic blood pressure to lower body negative pressure.
Neither absolute nor proportionate responses of sympathetic nerve activity during lower body negative pressure differed between placebo (8 ± 2 bursts/min; 20% ± 6%) and prednisone (5 ± 1 bursts/min; 21% ± 7%) treatments (Table I; Fig. 2) . The mean absolute and proportionate increments in plasma nor epinephrine levels during lower body negative pres sure were not significantly changed by prednisone treatment (0.30 ± 0.06 versus 0.42 ± 0.11 nmol/L and 34% ± 8% versus 27% ± 6%; Table I; Fig. 2 ). After prednisone, plasma dihydroxyphenylglycol lev els during lower body negative pressure increased by 10% ± 3 % (p < 0.01; Table I), an amount that did not differ from that after placebo. Responses of plasma epinephrine, dihydroxyphenylalanine, and di hydroxyphenylacetic acid levels during lower body negative pressure also did not differ between the two treatments. ANOVA revealed no significant interac tion effects between prednisone treatment and re sponses of any of the dependent neuronal or neuro chemical measures during lower body negative pressure.
Antecubital plasma norepinephrine levels correlated positively with sympathetic nerve activity levels (aver age correlation coefficient, 0.67; p < 0.01; Fig. 3 ). Prednisone treatment did not change the relationship between sympathetic nerve activity and plasma nor epinephrine levels at baseline or during lower body negative pressure (Fig. 3) .
DISCUSSION
The main findings in this double-blind, placebocontrolled, randomized crossover study were that oral prednisone administration at a dose of 20 mg/day de creased directly recorded skeletal muscle sympathetic nerve traffic and concurrently decreased antecubital venous plasma levels of the sympathetic neurotrans mitter norepinephrine and of its intraneuronal metabo lite dihydroxyphenylglycol.
The results extend to humans previous observations from studies of laboratory animals in which 1 week of 96 Golczynska Prednisone treatment also did not alter relationships between sympathetic nerve activity and plasma levels of norepinephrine at baseline or during lower body negative pressure. These findings suggest that, in hu mans, glucocorticoids do not affect presynaptic modu lation of norepinephrine release from sympathetic nerves. Analogously, in pithed rats, glucocorticoid treatment does not alter plasma norepinephrine re sponses to electrical stimulation of the entire sympa thetic outflow. 24 The 24-hour urinary excretion of catecholamines re mained unchanged after prednisone treatment, despite decreased levels of sympathetic nerve activity and of antecubital plasma norepinephrine. The sympathoinhibitory effect of prednisone may be too brief and too small to affect daily urinary norepinephrine excre tion . In addition, local release of norepinephrine in the kidneys contributes importantly to urinary norepineph rine excretion,25 Because sympathetic neural outflows to various organs are differentiated,26 it is possible that prednisone did not suppress sympathoneural traf fic to the kidneys and therefore did not decrease uri nary norepinephrine excretion.
Lower body negative pressure produced small but significant decreases in systolic blood pressure during the placebo phase, whereas lower body negative pres sure increased heart rate without affecting systolic blood pressure during the prednisone phase. Because sympathoneural responses to lower body pressure did not differ between the placebo and pred nisone treatment phases, the results suggest that al tered postsynaptic responsiveness could have pro duced these small but statistically significant hemodynamic differences. Patients with Cushing's disease27 and subjects treated for 1 week with oral hy drocortisone 7 have been reported to have enhanced pressor and vasoconstrictor responses to exogenous norepinephrine. Patients with Cushing's disease also have increased cardiac sensitivity to isoproterenol.28 Analogously, arterial walls and cardiac tissue from rats treated with dexamethasone have increased postsynaptic sensitivity to catecholamines. 29 This could be explained by an ability of dexamethasone to increase gene expression for a r-adrenergic receptors in smooth muscle cells. 30 With use of a highly sensitive radioimmunoassay for corticotropin, and consistent timing o f blood sam pling, this study revealed decreased corticotropin plasma levels during prednisone treatment compar ing with placebo treatment in every subject tested, verifying that the dose of 20 mg/day prednisone was adequate to attenuate HPA activity, as reported in other studies.9 Nevertheless, simultaneously obtained cortisol levels remained unchanged. Other clinical studies have reported analogous dissociation between cortisol and corticotropin changes in normal subjects.31,32 Thus, factors other than corticotropin appear to contribute to regulation of adrenocortical se cretion .
In summary, the results of this study indicate that prednisone decreases sympathoneural outflows in healthy humans without affecting reflexive sympatho neural responses during lower body negative pressure, a laboratory model of orthostasis, and without affect ing modulation of norepinephrine release from sympa thetic nerves.
